XML 115 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Licensing Agreements, Suzhou Ribo Life Science Co., Ltd. (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2017
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned   $ 172,299 $ 120,911 $ 104,152 $ 110,304 $ 160,349 $ 110,927 $ 38,470 $ 36,874 $ 507,666 $ 346,620 $ 283,703
Suzhou Ribo Life Science Co., Ltd. [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront payment recorded as deferred revenue $ 2,000                      
Ownership interest percentage   9.00%               9.00%    
Maximum amount of payments receivable for license fees and substantive milestones   $ 152,900               $ 152,900    
Maximum amount of payments receivable for development milestones   13,300               13,300    
Maximum amount of payments receivable for commercialization milestones   138,400               $ 138,400    
Royalty percentage received on sales of drug                   20.00%    
Cumulative payments received   2,000               $ 2,000    
Next prospective milestone   3,300               3,300    
Revenue earned                   700    
Deferred revenue   $ 1,700               $ 1,700